Full-dose blood thinners reduce the need for organ support in moderately ill COVID-19 patients, but not in critically ill patients
National Institutes of Health (NIH) sent this bulletin at 08/04/2021 06:30 PM EDTHaving trouble viewing this email? View it as a Web page.
You are receiving this message because you are subscribed to News Releases for National Institutes of Health (NIH).
08/04/2021 05:15 PM EDT
The final analysis of trial data included 1,098 critically ill and 2,219 moderately ill hospitalized patients who received either a low or full dose of heparin for up to 14 days after enrollment.
|
Update Your E-mail Address | Add Subscriptions | Unsubscribe All If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. For all other inquiries about NIH programs and activities, please contact Ask NIH. Before writing, please view our Frequently Asked Questions page, our Health Information page, or Search our website. This service is provided to you by the National Institutes of Health.
|
